Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-12

AUTHORS

Liliane Hobeika, Sally E Self, Juan Carlos Q Velez

ABSTRACT

BACKGROUND: Proteasome inhibitors are a relatively new class of chemotherapeutic agents. Bortezomib is the first agent of this class and is currently being used for the treatment of multiple myeloma. However, recent reports have linked exposure to bortezomib with the development of thrombotic microangiopathy. A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma. We report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with refractory multiple myeloma. CASE PRESENTATION: A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants. After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks. Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 μmol/L). Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma. Six weeks later, he developed abrupt worsening of lower extremity edema and hypertension, and new onset proteinuria. His kidney function remained stable. Kidney biopsy findings were consistent with thrombotic microangiopathy. Eight weeks after discontinuation of carfilzomib, proteinuria and hypertension improved. Due to progression of multiple myeloma, he died a few months later. CONCLUSION: In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient. More... »

PAGES

156

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1471-2369-15-156

DOI

http://dx.doi.org/10.1186/1471-2369-15-156

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1047232947

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25267524


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acute Kidney Injury", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Boronic Acids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bortezomib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dexamethasone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Edema", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fatal Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematopoietic Stem Cell Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension, Renal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lenalidomide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multiple Myeloma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligopeptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Podocytes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proteasome Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proteinuria", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrazines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Shock, Septic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Teniposide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thalidomide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thrombotic Microangiopathies", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Louisville", 
          "id": "https://www.grid.ac/institutes/grid.266623.5", 
          "name": [
            "Division of Nephrology and Hypertension, Department of Medicine, University of Louisville, 615 South Preston Street, 40202, Louisville, KY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hobeika", 
        "givenName": "Liliane", 
        "id": "sg:person.01027631644.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01027631644.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical University of South Carolina", 
          "id": "https://www.grid.ac/institutes/grid.259828.c", 
          "name": [
            "Department of Pathology, Medical University of South Carolina, Charleston, SC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Self", 
        "givenName": "Sally E", 
        "id": "sg:person.015017370564.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015017370564.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical University of South Carolina", 
          "id": "https://www.grid.ac/institutes/grid.259828.c", 
          "name": [
            "Division of Nephrology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Velez", 
        "givenName": "Juan Carlos Q", 
        "id": "sg:person.01131201727.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01131201727.91"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bmt.1701171", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006660654", 
          "https://doi.org/10.1038/sj.bmt.1701171"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1701171", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006660654", 
          "https://doi.org/10.1038/sj.bmt.1701171"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/10428190802023707", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009669974"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bcr-2012-006461", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011174364"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1046/j.1523-1755.2003.00071.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012605076", 
          "https://doi.org/10.1046/j.1523-1755.2003.00071.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1523-1755.2003.00071.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012605076"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3346/jkms.2014.29.5.648", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013160147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semnephrol.2010.09.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019546282"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.ki.5000055", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020678317", 
          "https://doi.org/10.1038/sj.ki.5000055"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc780", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024581782", 
          "https://doi.org/10.1038/nrc780"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc780", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024581782", 
          "https://doi.org/10.1038/nrc780"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.beha.2007.09.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025914764"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1745-6215-15-107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026028815", 
          "https://doi.org/10.1186/1745-6215-15-107"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/ndt/gft465", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028765304"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4081/hr.2012.e13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028803821"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4081/hr.2012.e13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028803821"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/qjmed/89.10.751", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031036405"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-008-0140-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032870534", 
          "https://doi.org/10.1007/s12185-008-0140-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-008-0140-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032870534", 
          "https://doi.org/10.1007/s12185-008-0140-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/petr.12300", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033543085"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.humpath.2014.05.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034050093"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1445-5994.2011.02458.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035735607"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0707330", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036840499"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1701830", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037910558", 
          "https://doi.org/10.1038/sj.bmt.1701830"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1701830", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037910558", 
          "https://doi.org/10.1038/sj.bmt.1701830"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1700791", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038194035", 
          "https://doi.org/10.1038/sj.bmt.1700791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1700791", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038194035", 
          "https://doi.org/10.1038/sj.bmt.1700791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2215/cjn.02070508", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038375943"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.1981.154", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040267576", 
          "https://doi.org/10.1038/clpt.1981.154"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-06-4086", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047843351"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1702849", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050017834", 
          "https://doi.org/10.1038/sj.bmt.1702849"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci115629", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050923946"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.atv.17.11.2793", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063334494"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4143/crt.2008.40.4.211", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072255766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4143/crt.2008.40.4.211", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072255766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079879530", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-12", 
    "datePublishedReg": "2014-12-01", 
    "description": "BACKGROUND: Proteasome inhibitors are a relatively new class of chemotherapeutic agents. Bortezomib is the first agent of this class and is currently being used for the treatment of multiple myeloma. However, recent reports have linked exposure to bortezomib with the development of thrombotic microangiopathy. A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma. We report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with refractory multiple myeloma.\nCASE PRESENTATION: A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants. After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks. Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 \u03bcmol/L). Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma. Six weeks later, he developed abrupt worsening of lower extremity edema and hypertension, and new onset proteinuria. His kidney function remained stable. Kidney biopsy findings were consistent with thrombotic microangiopathy. Eight weeks after discontinuation of carfilzomib, proteinuria and hypertension improved. Due to progression of multiple myeloma, he died a few months later.\nCONCLUSION: In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1471-2369-15-156", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024626", 
        "issn": [
          "1471-2369"
        ], 
        "name": "BMC Nephrology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "name": "Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma", 
    "pagination": "156", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e100a1ed1c0c036c6e3876c53f048e0a544eed553f78fa288565ba918c80d60d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25267524"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967793"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1471-2369-15-156"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1047232947"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1471-2369-15-156", 
      "https://app.dimensions.ai/details/publication/pub.1047232947"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000348_0000000348/records_54316_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2F1471-2369-15-156"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2369-15-156'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2369-15-156'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2369-15-156'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2369-15-156'


 

This table displays all metadata directly associated to this object as RDF triples.

294 TRIPLES      21 PREDICATES      86 URIs      49 LITERALS      37 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1471-2369-15-156 schema:about N063e22f5ba9647b1a2fb42e8865ba122
2 N0f21c7104e334d54b8762b02d093c324
3 N1916720274d5417d85c795e635ea2eb0
4 N2f7b2dbb8ebb4dc89da73016954c1639
5 N303280464f42441aa44f198cfcd05972
6 N39e8e479876446638035fb720c97fe98
7 N3e4f5b5b29ed47fc9312c29b12f982b8
8 N4023ca41b95e4b3b981a06f7e6eb2efd
9 N4521aebed63041dc8800b9bdd1ee9df0
10 N50cd098087bb47239604e11d15cb2514
11 N58d1e1a091234b62b6f482973b75ed3a
12 N6db86472a82843f781433028a98b9ef4
13 N6e30114f8db94c228997001868505227
14 N6fd9f2f770f949b38f8570e65a809fa2
15 N7606d367fb264066bba2f7bb69d6f9e5
16 N76d20126990e473b92c888434dfaf8ba
17 N8b58a635cc9249219b70da732ccdddf3
18 N9ba0657b30a74d40909429b4e648c8a3
19 Na0ef4c808dfa423ebdec1272ad7cef97
20 Nb5b12007b6614cad85b5ba3d4241b222
21 Nc18c250fec4d4715b24e6f80429c04b7
22 Nc2542083eb164317a2d5fa95e0a984a9
23 Nca1eea5e4d7e47dc95ad6ab4babdf63c
24 Nd0af6bddbb8c4982ac3ac6de3f7d6904
25 Nd1c8e5cf95584a3da31b9046d7f0e6c0
26 Necd5e16a54c14088ac1344bb83ea4299
27 Nece77f45982341d2b8437269bfb1b14b
28 Nf9bd8ed4b5fd40b581a47b5b380180a9
29 anzsrc-for:11
30 anzsrc-for:1103
31 schema:author Nd01c45ae0ea44c1e80420fda2fb0e6ed
32 schema:citation sg:pub.10.1007/s12185-008-0140-1
33 sg:pub.10.1038/clpt.1981.154
34 sg:pub.10.1038/nrc780
35 sg:pub.10.1038/sj.bmt.1700791
36 sg:pub.10.1038/sj.bmt.1701171
37 sg:pub.10.1038/sj.bmt.1701830
38 sg:pub.10.1038/sj.bmt.1702849
39 sg:pub.10.1038/sj.ki.5000055
40 sg:pub.10.1046/j.1523-1755.2003.00071.x
41 sg:pub.10.1186/1745-6215-15-107
42 https://app.dimensions.ai/details/publication/pub.1079879530
43 https://doi.org/10.1016/j.beha.2007.09.003
44 https://doi.org/10.1016/j.humpath.2014.05.015
45 https://doi.org/10.1016/j.semnephrol.2010.09.007
46 https://doi.org/10.1046/j.1523-1755.2003.00071.x
47 https://doi.org/10.1056/nejmoa0707330
48 https://doi.org/10.1080/10428190802023707
49 https://doi.org/10.1093/ndt/gft465
50 https://doi.org/10.1093/qjmed/89.10.751
51 https://doi.org/10.1111/j.1445-5994.2011.02458.x
52 https://doi.org/10.1111/petr.12300
53 https://doi.org/10.1136/bcr-2012-006461
54 https://doi.org/10.1158/0008-5472.can-06-4086
55 https://doi.org/10.1161/01.atv.17.11.2793
56 https://doi.org/10.1172/jci115629
57 https://doi.org/10.2215/cjn.02070508
58 https://doi.org/10.3346/jkms.2014.29.5.648
59 https://doi.org/10.4081/hr.2012.e13
60 https://doi.org/10.4143/crt.2008.40.4.211
61 schema:datePublished 2014-12
62 schema:datePublishedReg 2014-12-01
63 schema:description BACKGROUND: Proteasome inhibitors are a relatively new class of chemotherapeutic agents. Bortezomib is the first agent of this class and is currently being used for the treatment of multiple myeloma. However, recent reports have linked exposure to bortezomib with the development of thrombotic microangiopathy. A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma. We report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with refractory multiple myeloma. CASE PRESENTATION: A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants. After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks. Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 μmol/L). Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma. Six weeks later, he developed abrupt worsening of lower extremity edema and hypertension, and new onset proteinuria. His kidney function remained stable. Kidney biopsy findings were consistent with thrombotic microangiopathy. Eight weeks after discontinuation of carfilzomib, proteinuria and hypertension improved. Due to progression of multiple myeloma, he died a few months later. CONCLUSION: In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient.
64 schema:genre research_article
65 schema:inLanguage en
66 schema:isAccessibleForFree true
67 schema:isPartOf N2e4aa1916bf64a92a1409c331bd7ca23
68 Na3aa10d623ae452c807301db606d616f
69 sg:journal.1024626
70 schema:name Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma
71 schema:pagination 156
72 schema:productId N6db58b63ac284d2c9d25f9ca7fdee98c
73 N830bfec4993a450299c3fde5383e9943
74 Nae45de5084f24564bef5fddd891baa5c
75 Nbc804c54430843b2a9cd2cdc59573ae5
76 Nfea9569a8b3a4c3eb679241b97bdba94
77 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047232947
78 https://doi.org/10.1186/1471-2369-15-156
79 schema:sdDatePublished 2019-04-11T10:18
80 schema:sdLicense https://scigraph.springernature.com/explorer/license/
81 schema:sdPublisher N8febb7f63f51455b9fc5cc0a57407c28
82 schema:url https://link.springer.com/10.1186%2F1471-2369-15-156
83 sgo:license sg:explorer/license/
84 sgo:sdDataset articles
85 rdf:type schema:ScholarlyArticle
86 N05d9b1f50673490aa006e3c4a6a095b6 rdf:first sg:person.01131201727.91
87 rdf:rest rdf:nil
88 N063e22f5ba9647b1a2fb42e8865ba122 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Proteasome Inhibitors
90 rdf:type schema:DefinedTerm
91 N0f21c7104e334d54b8762b02d093c324 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Teniposide
93 rdf:type schema:DefinedTerm
94 N1916720274d5417d85c795e635ea2eb0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Antineoplastic Agents
96 rdf:type schema:DefinedTerm
97 N2e4aa1916bf64a92a1409c331bd7ca23 schema:issueNumber 1
98 rdf:type schema:PublicationIssue
99 N2f7b2dbb8ebb4dc89da73016954c1639 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Cyclophosphamide
101 rdf:type schema:DefinedTerm
102 N303280464f42441aa44f198cfcd05972 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Dexamethasone
104 rdf:type schema:DefinedTerm
105 N39e8e479876446638035fb720c97fe98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Proteinuria
107 rdf:type schema:DefinedTerm
108 N3e4f5b5b29ed47fc9312c29b12f982b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Edema
110 rdf:type schema:DefinedTerm
111 N4023ca41b95e4b3b981a06f7e6eb2efd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Bortezomib
113 rdf:type schema:DefinedTerm
114 N4521aebed63041dc8800b9bdd1ee9df0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Thrombotic Microangiopathies
116 rdf:type schema:DefinedTerm
117 N50cd098087bb47239604e11d15cb2514 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Middle Aged
119 rdf:type schema:DefinedTerm
120 N58d1e1a091234b62b6f482973b75ed3a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Combined Modality Therapy
122 rdf:type schema:DefinedTerm
123 N6db58b63ac284d2c9d25f9ca7fdee98c schema:name dimensions_id
124 schema:value pub.1047232947
125 rdf:type schema:PropertyValue
126 N6db86472a82843f781433028a98b9ef4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Antineoplastic Combined Chemotherapy Protocols
128 rdf:type schema:DefinedTerm
129 N6e30114f8db94c228997001868505227 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Lenalidomide
131 rdf:type schema:DefinedTerm
132 N6fd9f2f770f949b38f8570e65a809fa2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Disease Progression
134 rdf:type schema:DefinedTerm
135 N7606d367fb264066bba2f7bb69d6f9e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Hypertension, Renal
137 rdf:type schema:DefinedTerm
138 N76d20126990e473b92c888434dfaf8ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Multiple Myeloma
140 rdf:type schema:DefinedTerm
141 N830bfec4993a450299c3fde5383e9943 schema:name readcube_id
142 schema:value e100a1ed1c0c036c6e3876c53f048e0a544eed553f78fa288565ba918c80d60d
143 rdf:type schema:PropertyValue
144 N8b58a635cc9249219b70da732ccdddf3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Humans
146 rdf:type schema:DefinedTerm
147 N8febb7f63f51455b9fc5cc0a57407c28 schema:name Springer Nature - SN SciGraph project
148 rdf:type schema:Organization
149 N9ba0657b30a74d40909429b4e648c8a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Podocytes
151 rdf:type schema:DefinedTerm
152 Na0ef4c808dfa423ebdec1272ad7cef97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Acute Kidney Injury
154 rdf:type schema:DefinedTerm
155 Na3aa10d623ae452c807301db606d616f schema:volumeNumber 15
156 rdf:type schema:PublicationVolume
157 Nae45de5084f24564bef5fddd891baa5c schema:name pubmed_id
158 schema:value 25267524
159 rdf:type schema:PropertyValue
160 Nb1d279264c3a4427a41d5ae2d3b83589 rdf:first sg:person.015017370564.33
161 rdf:rest N05d9b1f50673490aa006e3c4a6a095b6
162 Nb5b12007b6614cad85b5ba3d4241b222 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Shock, Septic
164 rdf:type schema:DefinedTerm
165 Nbc804c54430843b2a9cd2cdc59573ae5 schema:name doi
166 schema:value 10.1186/1471-2369-15-156
167 rdf:type schema:PropertyValue
168 Nc18c250fec4d4715b24e6f80429c04b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Thalidomide
170 rdf:type schema:DefinedTerm
171 Nc2542083eb164317a2d5fa95e0a984a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Male
173 rdf:type schema:DefinedTerm
174 Nca1eea5e4d7e47dc95ad6ab4babdf63c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Oligopeptides
176 rdf:type schema:DefinedTerm
177 Nd01c45ae0ea44c1e80420fda2fb0e6ed rdf:first sg:person.01027631644.51
178 rdf:rest Nb1d279264c3a4427a41d5ae2d3b83589
179 Nd0af6bddbb8c4982ac3ac6de3f7d6904 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Pyrazines
181 rdf:type schema:DefinedTerm
182 Nd1c8e5cf95584a3da31b9046d7f0e6c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Fatal Outcome
184 rdf:type schema:DefinedTerm
185 Necd5e16a54c14088ac1344bb83ea4299 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Recurrence
187 rdf:type schema:DefinedTerm
188 Nece77f45982341d2b8437269bfb1b14b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Hematopoietic Stem Cell Transplantation
190 rdf:type schema:DefinedTerm
191 Nf9bd8ed4b5fd40b581a47b5b380180a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Boronic Acids
193 rdf:type schema:DefinedTerm
194 Nfea9569a8b3a4c3eb679241b97bdba94 schema:name nlm_unique_id
195 schema:value 100967793
196 rdf:type schema:PropertyValue
197 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
198 schema:name Medical and Health Sciences
199 rdf:type schema:DefinedTerm
200 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
201 schema:name Clinical Sciences
202 rdf:type schema:DefinedTerm
203 sg:journal.1024626 schema:issn 1471-2369
204 schema:name BMC Nephrology
205 rdf:type schema:Periodical
206 sg:person.01027631644.51 schema:affiliation https://www.grid.ac/institutes/grid.266623.5
207 schema:familyName Hobeika
208 schema:givenName Liliane
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01027631644.51
210 rdf:type schema:Person
211 sg:person.01131201727.91 schema:affiliation https://www.grid.ac/institutes/grid.259828.c
212 schema:familyName Velez
213 schema:givenName Juan Carlos Q
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01131201727.91
215 rdf:type schema:Person
216 sg:person.015017370564.33 schema:affiliation https://www.grid.ac/institutes/grid.259828.c
217 schema:familyName Self
218 schema:givenName Sally E
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015017370564.33
220 rdf:type schema:Person
221 sg:pub.10.1007/s12185-008-0140-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032870534
222 https://doi.org/10.1007/s12185-008-0140-1
223 rdf:type schema:CreativeWork
224 sg:pub.10.1038/clpt.1981.154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040267576
225 https://doi.org/10.1038/clpt.1981.154
226 rdf:type schema:CreativeWork
227 sg:pub.10.1038/nrc780 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024581782
228 https://doi.org/10.1038/nrc780
229 rdf:type schema:CreativeWork
230 sg:pub.10.1038/sj.bmt.1700791 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038194035
231 https://doi.org/10.1038/sj.bmt.1700791
232 rdf:type schema:CreativeWork
233 sg:pub.10.1038/sj.bmt.1701171 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006660654
234 https://doi.org/10.1038/sj.bmt.1701171
235 rdf:type schema:CreativeWork
236 sg:pub.10.1038/sj.bmt.1701830 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037910558
237 https://doi.org/10.1038/sj.bmt.1701830
238 rdf:type schema:CreativeWork
239 sg:pub.10.1038/sj.bmt.1702849 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050017834
240 https://doi.org/10.1038/sj.bmt.1702849
241 rdf:type schema:CreativeWork
242 sg:pub.10.1038/sj.ki.5000055 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020678317
243 https://doi.org/10.1038/sj.ki.5000055
244 rdf:type schema:CreativeWork
245 sg:pub.10.1046/j.1523-1755.2003.00071.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1012605076
246 https://doi.org/10.1046/j.1523-1755.2003.00071.x
247 rdf:type schema:CreativeWork
248 sg:pub.10.1186/1745-6215-15-107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026028815
249 https://doi.org/10.1186/1745-6215-15-107
250 rdf:type schema:CreativeWork
251 https://app.dimensions.ai/details/publication/pub.1079879530 schema:CreativeWork
252 https://doi.org/10.1016/j.beha.2007.09.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025914764
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1016/j.humpath.2014.05.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034050093
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1016/j.semnephrol.2010.09.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019546282
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1046/j.1523-1755.2003.00071.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1012605076
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1056/nejmoa0707330 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036840499
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1080/10428190802023707 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009669974
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1093/ndt/gft465 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028765304
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1093/qjmed/89.10.751 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031036405
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1111/j.1445-5994.2011.02458.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1035735607
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1111/petr.12300 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033543085
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1136/bcr-2012-006461 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011174364
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1158/0008-5472.can-06-4086 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047843351
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1161/01.atv.17.11.2793 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063334494
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1172/jci115629 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050923946
279 rdf:type schema:CreativeWork
280 https://doi.org/10.2215/cjn.02070508 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038375943
281 rdf:type schema:CreativeWork
282 https://doi.org/10.3346/jkms.2014.29.5.648 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013160147
283 rdf:type schema:CreativeWork
284 https://doi.org/10.4081/hr.2012.e13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028803821
285 rdf:type schema:CreativeWork
286 https://doi.org/10.4143/crt.2008.40.4.211 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072255766
287 rdf:type schema:CreativeWork
288 https://www.grid.ac/institutes/grid.259828.c schema:alternateName Medical University of South Carolina
289 schema:name Department of Pathology, Medical University of South Carolina, Charleston, SC, USA
290 Division of Nephrology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA
291 rdf:type schema:Organization
292 https://www.grid.ac/institutes/grid.266623.5 schema:alternateName University of Louisville
293 schema:name Division of Nephrology and Hypertension, Department of Medicine, University of Louisville, 615 South Preston Street, 40202, Louisville, KY, USA
294 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...